Engineering Archeal Surrogate Systems for the Development of Protein–Protein Interaction Inhibitors against Human RAD51

Journal of Molecular Biology

Volumn 428, Issue 23, 2016, Pages 4589-4607

  Moschetti, Tommaso ^a   Sharpe, Timothy ^a   Fischer, Gerhard ^a   Marsh, May E ^a   Ng, Hong Kin ^a   Morgan, Matthew ^a   Scott, Duncan E ^a   Blundell, Tom L ^a   Venkitaraman, Ashok R ^b   Skidmore, John ^a   Abell, Chris ^a   Hyvönen, Marko ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

fragment based drug discovery; humanisation; protein engineering; recombinase; surrogate system

Indexed keywords

BRCA2 PROTEIN; CHIMERIC PROTEIN; MUTANT PROTEIN; PROTEIN; RAD51 PROTEIN; RADA PROTEIN; UNCLASSIFIED DRUG; ARCHAEAL PROTEIN; BRCA2 PROTEIN, HUMAN; DNA BINDING PROTEIN; ENZYME INHIBITOR; PROTEIN BINDING; RAD51 PROTEIN, HUMAN; RADA PROTEIN, ARCHAEAL; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG DEVELOPMENT; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PYROCOCCUS FURIOSUS; THERMOSTABILITY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; PROCEDURES; PYROCOCCUS;

ARCHAEAL PROTEINS; BRCA2 PROTEIN; DNA-BINDING PROTEINS; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN ENGINEERING; PYROCOCCUS; RAD51 RECOMBINASE; RECOMBINANT PROTEINS;

EID: 84995561945     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2016.10.009     Document Type: Article

References (69)

1. [1] Overington, J.P., Al-Lazikani, B., Hopkins, A.L., How many drug targets are there?. Nat. Rev. Drug Discov. 5 (2006), 993–996, 10.1038/nrd2199.
2. [2] Venkatesan, K., Rual, J.-F., Vazquez, A., Stelzl, U., Lemmens, I., Hirozane-Kishikawa, T., Hao, T., Zenkner, M., Xin, X., Goh, K.-I., Yildirim, M.A., Simonis, N., Heinzmann, K., Gebreab, F., Sahalie, J.M., Cevik, S., Simon, C., de Smet, A.-S., Dann, E., Smolyar, A., Vinayagam, A., Yu, H., Szeto, D., Borick, H., Dricot, A., Klitgord, N., Murray, R.R., Lin, C., Lalowski, M., Timm, J., Rau, K., Boone, C., Braun, P., Cusick, M.E., Roth, F.P., Hill, D.E., Tavernier, J., Wanker, E.E., Barabási, A.-L., Vidal, M., An empirical framework for binary interactome mapping. Nat. Methods 6 (2009), 83–90, 10.1038/nmeth.1280.
3. [3] Fuller, J.C., Burgoyne, N.J., Jackson, R.M., Predicting druggable binding sites at the protein–protein interface. Drug Discov. Today 14 (2009), 155–161, 10.1016/j.drudis.2008.10.009.
4. [4] Surade, S., Blundell, T.L., Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem. Biol. 19 (2012), 42–50, 10.1016/j.chembiol.2011.12.013.
5. [5] Coyne, A.G., Scott, D.E., Abell, C., Drugging challenging targets using fragment-based approaches. Curr. Opin. Chem. Biol. 14 (2010), 299–307, 10.1016/j.cbpa.2010.02.010.
6. [6] Arkin, M.R., Tang, Y., Wells, J.A., Small-molecule inhibitors of protein–protein interactions: progressing toward the reality. Chem. Biol. 21 (2014), 1102–1114, 10.1016/j.chembiol.2014.09.001.
7. [7] van Gent, D.C., Hoeijmakers, J.H., Kanaar, R., Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. Genet. 2 (2001), 196–206, 10.1038/35056049.
8. [8] Su, X., Bernal, J.A., Venkitaraman, A.R., Cell-cycle coordination between DNA replication and recombination revealed by a vertebrate N-end rule degron-Rad51. Nat. Struct. Mol. Biol. 15 (2008), 1049–1058, 10.1038/nsmb.1490.
9. [9] Sonoda, E., Sasaki, M.S., Buerstedde, J.M., Bezzubova, O., Shinohara, A., Ogawa, H., Takata, M., Yamaguchi-Iwai, Y., Takeda, S., Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J. 17 (1998), 598–608, 10.1093/emboj/17.2.598.
10. [10] Lin, Z., Kong, H., Nei, M., Ma, H., Origins and evolution of the recA/RAD51 gene family: evidence for ancient gene duplication and endosymbiotic gene transfer. Proc. Natl. Acad. Sci. 103 (2006), 10328–10333, 10.1073/pnas.0604232103.
11. [11] Venkitaraman, A.R., Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 343 (2014), 1470–1475, 10.1126/science.1252230.
12. [12] Yuan, S.S.F., Lee, S.Y., Chen, G., Song, M., Tomlinson, G.E., Lee, E.Y.H.P., BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 59 (1999), 3547–3551.
13. [13] Yu, V.P.C.C., Koehler, M., Steinlein, C., Schmid, M., Hanakahi, L.A., Van Gool, A.J., West, S.C., Venkitaraman, A.R., Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev. 14 (2000), 1400–1406, 10.1101/gad.14.11.1400.
14. [14] Yu, D.S., Sonoda, E., Takeda, S., Huang, C.L.H., Pellegrini, L., Blundell, T.L., Venkitaraman, A.R., Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2. Mol. Cell 12 (2003), 1029–1041, 10.1016/S1097-2765(03)00394-0.
15. [15] Jeyasekharan, A.D., Liu, Y., Hattori, H., Pisupati, V., Jonsdottir, A.B., Rajendra, E., Lee, M., Sundaramoorthy, E., Schlachter, S., Kaminski, C.F., Ofir-Rosenfeld, Y., Sato, K., Savill, J., Ayoub, N., Venkitaraman, A.R., A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization. Nat. Struct. Mol. Biol. 20 (2013), 1191–1198, 10.1038/nsmb.2666.
16. [16] Shivji, M.K.K., Davies, O.R., Savill, J.M., Bates, D.L., Pellegrini, L., Venkitaraman, A.R., A region of human BRCA2 containing multiple BRC repeats promotes RAD51-mediated strand exchange. Nucleic Acids Res. 34 (2006), 4000–4011, 10.1093/nar/gkl505.
17. [17] Carreira, A., Hilario, J., Amitani, I., Baskin, R.J., Shivji, M.K.K., Venkitaraman, A.R., Kowalczykowski, S.C., The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51. Cell 136 (2009), 1032–1043, 10.1016/j.cell.2009.02.019.
18. [18] Shivji, M.K.K., Mukund, S.R., Rajendra, E., Chen, S., Short, J.M., Savill, J., Klenerman, D., Venkitaraman, A.R., The BRC repeats of human BRCA2 differentially regulate RAD51 binding on single- versus double-stranded DNA to stimulate strand exchange. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 13,254–13,259, 10.1073/pnas.0906208106.
19. [19] Liu, J., Doty, T., Gibson, B., Heyer, W.-D., Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat. Struct. Mol. Biol. 17 (2010), 1260–1262, 10.1038/nsmb.1904.
20. [20] Jensen, R.B., Carreira, A., Kowalczykowski, S.C., Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467 (2010), 678–683, 10.1038/nature09399.
21. [21] Thorslund, T., McIlwraith, M.J., Compton, S.a., Lekomtsev, S., Petronczki, M., Griffith, J.D., West, S.C., The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nat. Struct. Mol. Biol. 17 (2010), 1263–1265, 10.1038/nsmb.1905.
22. [22] Patel, K.J., Yu, V.P., Lee, H., Corcoran, A., Thistlethwaite, F.C., Evans, M.J., Colledge, W.H., Friedman, L.S., Ponder, B.A.J., Venkitaraman, A.R., Involvement of BRCA2 in DNA repair. Mol. Cell 1 (1998), 347–357, 10.1016/S1097–2765(00)80035-0.
23. [23] Chen, P.L., Chen, C.F., Chen, Y., Xiao, J., Sharp, Z.D., Lee, W.H., The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 5287–5292, 10.1073/pnas.95.9.5287.
24. [24] Klein, H.L., The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 7 (2008), 686–693, 10.1016/j.dnarep.2007.12.008.
25. [25] Pellegrini, L., Yu, D.S., Lo, T., Anand, S., Lee, M., Blundell, T.L., Venkitaraman, A.R., Insights into DNA recombination from the structure of a RAD51–BRCA2 complex. Nature 420 (2002), 287–293, 10.1038/nature01230.
26. [26] Shin, D.S., Pellegrini, L., Daniels, D.S., Yelent, B., Craig, L., Bates, D., Yu, D.S., Shivji, M.K., Hitomi, C., Arvai, A.S., Volkmann, N., Tsuruta, H., Blundell, T.L., Venkitaraman, A.R., Tainer, J.A., Full-length archaeal Rad51 structure and mutants: mechanisms for RAD51 assembly and control by BRCA2. EMBO J. 22 (2003), 4566–4576, 10.1093/emboj/cdg429.
27. [27] Conway, A.B., Lynch, T.W., Zhang, Y., Fortin, G.S., Fung, C.W., Symington, L.S., Rice, P.A., Crystal structure of a Rad51 filament. Nat. Struct. Mol. Biol. 11 (2004), 791–796, 10.1038/nsmb795.
28. [28] Wu, Y., Qian, X., He, Y., Moya, I.A., Luo, Y., Crystal structure of an ATPase-active form of Rad51 homolog from Methanococcus voltae. Insights into potassium dependence. J. Biol. Chem. 280 (2005), 722–728, 10.1074/jbc.M411093200.
29. [29] Lo, T., Pellegrini, L., Venkitaraman, A.R., Blundell, T.L., Sequence fingerprints in BRCA2 and RAD51: implications for DNA repair and cancer. DNA Repair (Amst) 2 (2003), 1015–1028, 10.1016/S1568-7864(03)00097-1.
30. [30] Scott, D.E., Marsh, M., Blundell, T.L., Abell, C., Hyvönen, M., Structure–activity relationship of the peptide binding-motif mediating the BRCA2:RAD51 protein–protein interaction. FEBS Lett. 590 (2016), 1094–1102, 10.1002/1873-3468.12139.
31. [31] Rajendra, E., Venkitaraman, A.R., Two modules in the BRC repeats of BRCA2 mediate structural and functional interactions with the RAD51 recombinase. Nucleic Acids Res. 38 (2010), 82–96, 10.1093/nar/gkp873.
32. [32] Davies, A.A., Masson, J.Y., McIlwraith, M.J., Stasiak, A.Z., Stasiak, A., Venkitaraman, A.R., West, S.C., Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol. Cell 7 (2001), 273–282 ( http://www.ncbi.nlm.nih.gov/pubmed/11239456).
33. [33] Pellegrini, L., Venkitaraman, A., Emerging functions of BRCA2 in DNA recombination. Trends Biochem. Sci. 29 (2004), 310–316, 10.1016/j.tibs.2004.04.009.
34. [34] Blundell, T.L., Sibanda, B.L., Montalvão, R.W., Brewerton, S., Chelliah, V., Worth, C.L., Harmer, N.J., Davies, O., Burke, D., Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 361 (2006), 413–423, 10.1098/rstb.2005.1800.
35. [35] Pommier, Y., Marchand, C., Interfacial inhibitors: targeting macromolecular complexes. Nat. Rev. Drug Discov. 11 (2011), 25–36, 10.1038/nrd3404.
36. [36] Scott, D.E., Coyne, A.G., Venkitaraman, A., Blundell, T.L., Abell, C., Hyvönen, M., Small-molecule inhibitors that target protein–protein interactions in the RAD51 family of recombinases. ChemMedChem 10 (2015), 296–303, 10.1002/cmdc.201402428.
37. [37] Scott, D.E., Ehebauer, M.T., Pukala, T., Marsh, M., Blundell, T.L., Venkitaraman, A.R., Abell, C., Hyvönen, M., Using a fragment-based approach to target protein–protein interactions. Chembiochem 14 (2013), 332–342, 10.1002/cbic.201200521.
38. [38] Marsh, M.E., Scott, D.E., Ehebauer, M.T., Abell, C., Blundell, T.L., Hyvönen, M., ATP half-sites in RadA and RAD51 recombinases bind nucleotides. FEBS Open Bio 6 (2016), 372–385, 10.1002/2211-5463.12052.
39. [39] Komori, K., Miyata, T., DiRuggiero, J., Holley-Shanks, R., Hayashi, I., Cann, I.K., Mayanagi, K., Shinagawa, H., Ishino, Y., Both RadA and RadB are involved in homologous recombination in Pyrococcus furiosus. J. Biol. Chem. 275 (2000), 33,782–33,790, 10.1074/jbc.M004557200.
40. [40] Subramanyam, S., Jones, W.T., Spies, M., Spies, M.A., Contributions of the RAD51 N-terminal domain to BRCA2–RAD51 interaction. Nucleic Acids Res. 41 (2013), 9020–9032, 10.1093/nar/gkt691.
41. [41] Davies, T.G., Verdonk, M.L., Graham, B., Saalau-Bethell, S., Hamlett, C.C.F., McHardy, T., Collins, I., Garrett, M.D., Workman, P., Woodhead, S.J., Jhoti, H., Barford, D., A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J. Mol. Biol. 367 (2007), 882–894, 10.1016/j.jmb.2007.01.004.
42. [42] Couty, S., Westwood, I.M., Kalusa, A., Cano, C., Travers, J., Boxall, K., Chow, C.L., Burns, S., Schmitt, J., Pickard, L., Barillari, C., McAndrew, P.C., Clarke, P.A., Linardopoulos, S., Griffin, R.J., Aherne, G.W., Raynaud, F.I., Workman, P., Jones, K., van Montfort, R.L.M., The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Oncotarget 4 (2013), 1647–1661 ( http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858552/nhttp://europepmc.org/abstract/MED/24072592).
43. [43] Zhang, H., Neimanis, S., Lopez-Garcia, L.A., Arencibia, J.M., Amon, S., Stroba, A., Zeuzem, S., Proschak, E., Stark, H., Bauer, A.F., Busschots, K., Jørgensen, T.J.D., Engel, M., Schulze, J.O., Biondi, R.M., Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound. Chem. Biol. 21 (2014), 754–765, 10.1016/j.chembiol.2014.04.007.
44. [44] Nishida, M., Cadene, M., Chait, B.T., MacKinnon, R., Crystal structure of a Kir3.1-prokaryotic Kir channel chimera. EMBO J. 26 (2007), 4005–4015, 10.1038/sj.emboj.7601828.
45. [45] Barren, B., Gakhar, L., Muradov, H., Boyd, K.K., Ramaswamy, S., Artemyev, N.O., Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit. EMBO J. 28 (2009), 3613–3622, 10.1038/emboj.2009.284.
46. [46] Vucic, D., Franklin, M.C., Wallweber, H.J.A., Das, K., Eckelman, B.P., Shin, H., Elliott, L.O., Kadkhodayan, S., Deshayes, K., Salvesen, G.S., Fairbrother, W.J., Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem. J. 385 (2005), 11–20, 10.1042/BJ20041108.
47. [47] Cohen, F., Alicke, B., Elliott, L.O., Flygare, J.A., Goncharov, T., Keteltas, S.F., Franklin, M.C., Frankovitz, S., Stephan, J.-P., Tsui, V., Vucic, D., Wong, H., Fairbrother, W.J., Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold. J. Med. Chem. 52 (2009), 1723–1730, 10.1021/jm801450c.
48. [48] Mileni, M., Johnson, D.S., Wang, Z., Everdeen, D.S., Liimatta, M., Pabst, B., Bhattacharya, K., Nugent, R.A., Kamtekar, S., Cravatt, B.F., Ahn, K., Stevens, R.C., Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 12,820–12,824, 10.1073/pnas.0806121105.
49. [49] Goihberg, E., Peretz, M., Tel-Or, S., Dym, O., Shimon, L., Frolow, F., Burstein, Y., Biochemical and structural properties of chimeras constructed by exchange of cofactor-binding domains in alcohol dehydrogenases from thermophilic and mesophilic microorganisms. Biochemistry 49 (2010), 1943–1953, 10.1021/bi901730x.
50. [50] Robic, S., Berger, J.M., Marqusee, S., Contributions of folding cores to the thermostabilities of two ribonucleases H. Protein Sci. 11 (2002), 381–389, 10.1110/ps.38602.
51. [51] Edwards, T.E., Liao, R., Phan, I., Myler, P.J., Grundner, C., Mycobacterium thermoresistibile as a source of thermostable orthologs of Mycobacterium tuberculosis proteins. Protein Sci. 21 (2012), 1093–1096, 10.1002/pro.2084.
52. [52] Schröder, K.H., Naumann, L., Kroppenstedt, R.M., Reischl, U., Mycobacterium hassiacum sp. nov., a new rapidly growing thermophilic mycobacterium. Int. J. Syst. Bacteriol. 47 (1997), 86–91 ( http://www.ncbi.nlm.nih.gov/pubmed/8995808).
53. [53] Mendes, V., Blaszczyk, M., Maranha, A., Empadinhas, N., Blundell, T.L., Structure of Mycobacterium thermoresistibile GlgE defines novel conformational states that contribute to the catalytic mechanism. Sci. Rep., 5, 2015, 17,144, 10.1038/srep17144.
54. [54] Baugh, L., Phan, I., Begley, D.W., Clifton, M.C., Armour, B., Dranow, D.M., Taylor, B.M., Muruthi, M.M., Abendroth, J., Fairman, J.W., Fox, D., Dieterich, S.H., Staker, B.L., Gardberg, A.S., Choi, R., Hewitt, S.N., Napuli, A.J., Myers, J., Barrett, L.K., Zhang, Y., Ferrell, M., Mundt, E., Thompkins, K., Tran, N., Lyons-Abbott, S., Abramov, A., Sekar, A., Serbzhinskiy, D., Lorimer, D., Buchko, G.W., Stacy, R., Stewart, L.J., Edwards, T.E., Van Voorhis, W.C., Myler, P.J., Increasing the structural coverage of tuberculosis drug targets. Tuberculosis 95 (2015), 142–148, 10.1016/j.tube.2014.12.003.
55. [55] Pires, D.E.V., Ascher, D.B., Blundell, T.L., mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics 30 (2014), 335–342, 10.1093/bioinformatics/btt691.
56. [56] Peränen, J., Rikkonen, M., Hyvönen, M., Kääriäinen, L., T7 vectors with modified T7lac promoter for expression of proteins in Escherichia coli. Anal. Biochem., 236, 1996, 371 ( http://www.ncbi.nlm.nih.gov/pubmed/8660525 (accessed January 10, 2011)).
57. [57] Brinkmann, U., Mattes, R., Buckel, P., High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product. Gene 85 (1989), 109–114 ( http://www.sciencedirect.com/science/article/pii/0378111989904708 accessed March 10, 2013).
58. [58] Golovanov, A.P., Hautbergue, G.M., Wilson, S.A., Lian, L.Y., A simple method for improving protein solubility and long-term stability. J. Am. Chem. Soc. 126 (2004), 8933–8939, 10.1021/ja049297h.
59. [59] Wang, Z.X., An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule. FEBS Lett. 360 (1995), 111–114, 10.1016/0014-5793(95)00062-E.
60. [60] Kabsch, W., XDS. Acta Crystallogr. Sect. D Biol. Crystallogr. 66 (2010), 125–132, 10.1107/S0907444909047337.
61. [61] Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., Bricogne, G., Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. Sect. D Biol. Crystallogr. 67 (2011), 293–302, 10.1107/S0907444911007773.
62. [62] Evans, P.R., Murshudov, G.N., How good are my data and what is the resolution?. Acta Crystallogr. Sect. D Biol. Crystallogr. 69 (2013), 1204–1214, 10.1107/S0907444913000061.
63. [63] Evans, P., Scaling and assessment of data quality. Acta Crystallogr. Sect. D Biol. Crystallogr. 62 (2006), 72–82, 10.1107/S0907444905036693.
64. [64] Trapani, S., Navaza, J., AMoRe: classical and modern. Acta Crystallogr. Sect. D Biol. Crystallogr. 64 (2008), 11–16, 10.1107/S0907444907044460.
65. [65] Murshudov, G.N., Skubák, P., Lebedev, A.a., Pannu, N.S., Steiner, R.a., Nicholls, R.a., Winn, M.D., Long, F., Vagin, A.a., REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. Sect. D Biol. Crystallogr. 67 (2011), 355–367, 10.1107/S0907444911001314.
66. [66] Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.-W., Kapral, G.J., Grosse-Kunstleve, R.W., McCoy, A.J., Moriarty, N.W., Oeffner, R., Read, R.J., Richardson, D.C., Richardson, J.S., Terwilliger, T.C., Zwart, P.H., PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66 (2010), 213–221, 10.1107/S0907444909052925.
67. [67] Smart, O., Brandl, M., Flensburg, C., Keller, P., Paciorek, W., Vonrhein, C., Womack, T., Bricogne, G., Refinement with local structure similarity restraints (LSSR) enables exploitation of information from related structures and facilitates use of NCS. Annu. Meet. Am. Crystallogr. Assoc., 2008, 117 https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwj_o7LvwNrPAhULLMAKHXeeAUcQFggeMAA&url=https%3A%2F%2Fwww.globalphasing.com%2Fbuster%2Fmanual%2Fgelly%2Fmanual%2Faca_abstract.pdf&usg=AFQjCNEHbJ0m43hIkqAW6lSa8eFao6Xpkw&sig2=Z8efhU0yNtC5RXWfwuyv2w&cad=rja.
68. [68] Emsley, P., Lohkamp, B., Scott, W.G., Cowtan, K., Features and development of Coot. Acta Crystallogr. Sect. D Biol. Crystallogr. 66 (2010), 486–501, 10.1107/S0907444910007493.
69. [69] Smart, O.S., Womack, T.O., Sharff, A., Flensburg, C., Keller, P., Paciorek, W., Vonrhein, C., Bricogne, G., Grade, Web Server v1.102. 2011, Glob. Phasing Ltd., Cambridge, United Kingdom.